Mark Blaskovich

Dr. Mark Blaskovich is a Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and a Senior Research Officer at the Institute for Molecular Bioscience at The University of Queensland. He has extensive medicinal chemistry expertise and over 15 years of industrial drug development experience gained at three biotech companies, most recently as Chief Operating Officer of Mimetica (Australia), where he managed the drug discovery and development program for MC5-R antagonists, producing a compound that recently completed a Phase II clinical trial. Since starting at The University of Queensland, Mark has been developing new antibiotics to treat drug resistant pathogens and creating antibiotic-derived fluorescent probes to investigate antimicrobial resistance. He has published over forty research articles as well as a book on amino acid synthesis and he is an inventor on eight patent families encompassing over 50 granted patents.